Treating newborns with antiretroviral therapy in the hours after birth may help put HIV into remission.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
On behalf of IFARA, executive producer Fred Schaich spoke with Seema Desai, Ph.D., Peter Hunt, M.D., and Alan Landay, Ph.D., about managing HIV in those over 50 years old.
The ACTG A5303 study at CROI 2015 was a double-blind, randomized trial that compared maraviroc (Selzentry, Celsentri), at 150 mg once daily, to tenofovir (TDF, Viread) in 259 treatment-naive patients, both arms with ritonavir (Norvir)-boosted darunav...
Having a high viral load when starting treatment was most consistently associated with body composition changes after starting antiretroviral therapy.
A person living with HIV can transmit the virus during the first six months of starting treatment. Researchers suggest extra prevention strategies for mixed-status couples during this period before viral suppression is achieved.
Two studies presented at CROI 2015 provided results that describe the benefits to starting HIV treatment early, in terms of time (within three months of infection) and in terms of CD4 count (greater than 350 cells).
Researchers found that people with higher viral loads when they first start ART are more likely to have substantial body composition changes than those who start treatment with a lower viral load.
U.S. treatment guidelines equally recommend first-line treatment regimens that include either a non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva, Stocrin); one of two ritonavir (Norvir)-boosted protease inhibitors (PIs), ata...